SCHEMBL5528503

SCHEMBL5528503

C=CCNC(=O)NC(CC(=O)NCC#N)C1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.42
NPSR1 Q6W5P4 1/20 0.42
CTSL P07711 4/20 0.37
CTSK P43235 5/20 0.36
CTSS P25774 4/20 0.34
CTSB P07858 4/20 0.33
KMT2A Q03164 2/20 0.33
DPP4 P27487 2/20 0.33
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
GAA P10253 1/20 0.30
LMNA P02545 1/20 0.30
EPHX2 P34913 2/20 0.30
EPHX1 P07099 1/20 0.30
TRPV1 Q8NER1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5523195 0.84 CTSK (0.42) CTSLCTSKCTSSCTSBDPP4
SCHEMBL5528435 0.83 EPHX1 (0.47) ALDH1A1CTSLNPC1RAB9ALMNA
SCHEMBL5523597 0.81 CTSK (0.40) ALDH1A1CTSLCTSKCTSSCTSB
SCHEMBL5530341 0.79 EPHX1 (0.51) EPHX2EPHX1
SCHEMBL5527518 0.78 EPHX2 (0.47) CTSLCTSKCTSSCTSBKMT2A
SCHEMBL5529123 0.77 CTSK (0.36) CTSLCTSKCTSSCTSBDPP4
SCHEMBL5522925 0.76 EPHX2 (0.54) ALDH1A1CTSLCTSKCTSSCTSB
SCHEMBL5523563 0.75 CTSK (0.39) ALDH1A1NPSR1CTSLCTSKCTSS
SCHEMBL5523564 0.74 CTSK (0.39) CTSLCTSKCTSSCTSBDPP4
SCHEMBL5518398 0.73 PPARG (0.43) ALDH1A1CTSLCTSKCTSSCTSB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed
EP-1178958-A2 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-02-13 EP disclosed
WO-2000055125-A2 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 ALDH1A1 4049/4885NPSR1 1833/4885CTSL 14/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 ALDH1A1 4049/4885NPSR1 1833/4885CTSL 14/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.